Log in to post a reply
Dec 10, 2019 10:38PM
Thanks so much dtad. I agree, we should have our feelings and experiences validated, but feels like that is often an uphill battle.
I think you are so right, that sexism influences how the bc industry and society at large treat us. Men wouldn't put up with half of the humiliating and debasing things done to us " for our benefit " Bullsh*t. The entire medical industrial complex makes a friggin ton of money off of each and every ine of us tortured women.
WHY DO THOSE MEN ALL GET SO MUCH MONEY THEY DON'T DESERVE???
THEY PROFIT OFF THE OUR SUFFERING AND PAIN. THERE WERE TIMES I COULDN'T AFFORD TO BUY GAS FOR MY CAR
SHAME ON THEM!
According to our data, Roche Holding AG has a market capitalization of CHF235b, and pays its CEO total annual compensation worth CHF12m. (This is based on the year to December 2018). That's actually a decrease on the year before.Jul 1, 2019Simply Wall St › st › stocks › is-roc... Is Roche Holding AG's (VTX:ROG) CEO Pay Justified? – Simply Wall St News
Executive CompensationAs Chief Executive Officer and President at AMGEN INC, Robert A. Bradway made $18,555,266 in total compensation.Salary.com › Robert-A-Bradway-Sal... Compensation Information for Robert A. Bradway , Chief Executive Officer and President of AMGEN INC | Salary.com
$10 millionNovartis chief's 2018 take-home pay suffers—not from Cohen but from low-grade returns. Novartis CEO Vas Narasimhan navigated through a tough and transitional year at the drugmaker, racking up almost $10 million in salary, incentive pay and equity awards for his efforts.Feb 12, 2019FiercePharma › pharma › compared... Novartis CEO tots up $10M in 2018, with top marks for innovation - FiercePharma
Who's not among the top 10 cancer drug developers in the world by sales? Some surprisingly big names, such as AbbVie, Biogen Idec, GlaxoSmithKline, Sanofi, and Pfizer. Of course, Pfizer's luck could change with the possible approval of palbociclib.
But, even more high-profile names are left out of the top three. Bristol-Myers Squibb, Merck, AstraZeneca, Eli Lilly, Johnson & Johnson, and Celgene make up spots nine through four. Combined, these six companies were responsible for $24.4 billion in cancer drug sales in 2013. Yet, the No. 1 company on the list sold more oncology drugs than these six companies combined!
Three companies responsible for half of all global cancer drug sales
Here's a breakdown of the three companies that controlled roughly half of all cancer drug sales in 2013.
No. 3: Novartis (NYSE:NVS): $8.6 billion in total oncology drug sales
Novartis' appearance on this list probably shouldn't be a huge surprise as it's been a cancer drug powerhouse for quite some time. In 2013, it counted on chronic myeloid leukemia drug Gleevec (known as Glivec overseas) for nearly $4.7 billion in global sales, but also relied on Sandostatin (for acromegaly) and Afinitor (breast cancer) for $1.6 billion and $1.3 billion in global sales.
No. 2: Amgen (NASDAQ:AMGN): $11.9 billion in total oncology drug sales
Surprised by Amgen's ranking? Don't be, as the company has a long history of supportive cancer care therapies. Neulasta (known as Neupogen overseas), is a roughly $6 billion per year drug designed to stimulate white blood cell growth for patients currently undergoing chemotherapy. Aranesp is responsible for another $2 billion in annual sales.
No. 1: Roche (OTC:RHHBY): $25.4 billion in total oncology drug sales
Sitting atop the list of annual cancer drug sales is Swiss-based Roche, which generated more than one quarter of all oncology drug sales in 2013 by itself! But, should we really be surprised with Roche currently possessing a clinical pipeline that's more than 100 trials deep, of which around 60 of those studies are for cancer indications? I'm not shocked one bit!